8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): September 28, 2010

STEREOTAXIS, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

000-50884	94-3120386
(Commission File Number)	(IRS Employer Identification No.)

4320 Forest Park Avenue, Suite 100, St. Louis, Missouri	63108
(Address of Principal Executive Offices)	(Zip Code)

(314) 678-6100

(Registrant’s Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

On September 28, 2010, executive management of Stereotaxis, Inc. (the “Company”) will present at the Fifth Annual JMP Securities Healthcare Conference. The investor presentation slides are being furnished as Exhibit 99.1 and can be accessed on the Investor Relations portion of the Company’s website at http://www.stereotaxis.com/Investor-Relations.

The presentation slides are being furnished pursuant to Item 7.01, and the information contained therein shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

The presentation slides that are attached to this Current Report on Form 8-K as Exhibit 99.1 include statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company’s products in the marketplace, the effect of global credit and economic conditions on the ability and willingness of customers to purchase our systems, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approval and return of the irrigated catheter to the market, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company’s control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Investor presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	STEREOTAXIS, INC.
Date: September 28, 2010	By:	/s/    DANIEL J. JOHNSTON
	Name:	Daniel J. Johnston
	Title:	Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Document
99.1	Investor presentation

EX-99.1

NASDAQ: STXS

Exhibit 99.1

Forward-Looking Statements

2

During the course of this presentation, the Company may make projections and other forward-

looking statements regarding future events or the future financial performance of the Company,

including without limitation, statements regarding future operating results, growth opportunities

and other statements that refer to Stereotaxis’ plans, prospects, expectations, strategies,

intentions and beliefs. These statements are subject to many risks and uncertainties that could

cause actual results to differ materially from expectations.

For a detailed discussion of risks and uncertainties that affect the Company’s business and

qualify the forward-looking statements made in this presentation, we refer you to the Company’s

recent public filings filed with the SEC, specifically the Form 10-K for the fiscal year ended

December 31, 2009.

The Company’s projections and forward-looking statements are based on factors that are subject

to change and therefore these statements speak only as of the date they are given. The

Company assumes no obligation to update any projections or forward-looking statements.

In addition, regarding orders and backlog, there can be no assurance that the Company will

recognize revenue related to its purchase orders and other commitments in any particular period,

or at all, because some of these purchase orders and other commitments are subject to

contingencies that are outside of our control. These orders and commitments may be revised,

modified, or canceled either by their express terms, as a result of negotiations, or by project

changes or delays.

Investment Considerations

Two innovative technology platforms:

Niobe

®

Magnetic Navigation System

Odyssey

™

Enterprise Solutions

Substantial IP portfolio

Large, fast growing (+20%) cardiology ablation market

Poised for continued growth in electrophysiology (EP)

Expansion into new markets

New geographic opportunities

Broad clinical applications beyond EP

Multi-dimensional strategy to accelerate growth

3

Niobe

Magnetic Navigation System

Magnet-guided catheter distal tip provides precise remote control of therapeutic

devices.

4

Niobe Provides Precision and Safety

Precise control of catheter distal tip provides:

Effective lesion creation through

constant contact

Exceptional mapping capability

Exemplary safety

Proven in all chambers of the heart

5

Manual

Niobe

Physician

Efficacy

Safety

Efficiency

In procedure room exposed to fluoroscopy

Physician:

Significant X-ray exposure

Patient:  Major event rate ~2.8%

Higher variability in procedure times

In control room outside fluoroscopy field

Clearly better in several applications

-

VT, pediatrics, congenital heart diseases

Other applications comparable to manual

Physician:

Almost no X-ray exposure

Patient:  Major event rate ~0.1%

Standardized process drives tighter

distribution around procedure times

High re-do rates

Niobe’s Advantages

6

Atrial

Fibrillation

30 Publications

Up

to

100%

acute

success

4

Improved

chronic

outcomes

5

Pediatric Arrhythmia

5 publications

93%

acute

success

3

Low fluoro, no complications

Congenital Heart

6 publications

90%

success

rate

6

“As easy as normal adults”

Ventricular Tachycardia

13 publications

Up

to

100%

acute

success

7

85%

freedom

at

1

year

8

Radiation Reduction

Patients –

67%

1

Physicians –

90%

2

1. Haghjoo,  JCE 2009.  2. Latcu, Arch Cardiovasc

Dis

2009.  3. Schwagten, PACE 2009.  4. DiBiase, JCE 2009.

5. Augello, Heart Rhythm 2009. 6. Schwagten, PACE 2009. 7. Haghjoo, JCE 2009.  8. Dibiase, Heart Rhythm 2009.

7

Strong Clinical Validation

More than 150 peer-reviewed publications highlight Niobe’s

value

Major Advantages in Ventricular Tachycardia Ablation

97%

24%

170

25

8

81%

28%

228

57

13

0

50

100

150

200

250

Acute Success (%)

Recurrence (%)

Case Time (min)

Fluoro Time (min)

RF Apps

STXS

Manual

p

= 0.03

p

< 0.01

p

< 0.001

NS

8

NS

•

VT is an abnormally fast heart rhythm that originates from one of the ventricles and can

lead to potentially life threatening complications.

•

64 consecutive VT ablation patients

–

37 Niobe; 27 manual procedures

–

Idiopathic & Scar-Related

•

No complications in Niobe

group

•

1 tamponade/death in manual group

•

Conclusion:

Niobe

offers

“major

clinical

&

cost

advantages

for

VT

ablation”

Schwagten, et al. Eur

Heart J 2010, 31 (Supp):932.

Global EP Market is Large and Growing

Source: Millennium Research Group (2009); Stereotaxis internal analysis

9

EP Procedures

Routine

AF

VT

Other

Total

Complex

Prevalence

Annual

Procedures

Annual

Growth

>20M

>10M

>3M

>5M

>18M

170K

100K

30K

40K

170K

<10%

25%

15%

15%

20%

Stereotaxis

focused on

complex

ablation, 

high-growth

segments

Niobe

Market Adoption & Procedure Growth

30,000 + procedures

Cumulative Procedures

Growing Worldwide Penetration

141 Systems Installed

60% US -

40% OUS

Canada -

3

United States -

77

Europe -

49

Saudi Arabia -

1

Russia -

1

China -

5

Korea -

1

Japan -

1

Singapore -

1

Taiwan -

1

Australia -

1

10

Odyssey Enterprise

TM

Solutions

11

Odyssey

Vision

Integrates and centralizes all EP lab related information to significantly enhance

physicians’

efficiency

The Odyssey Product Line

12

140 Niobe

Labs

CONNECT

CINEMA

VISION

Efficiently integrate

data and control

during procedures

Standardize all labs

to increase staff

effectiveness

Drive world-class

practices by capturing,

compressing and

recording data for

storage and networking

NIOBE

Accelerate clinical

education by playing

back synchronized lab

data

Drive quality of

patient care by

connecting clinical

experts

Build market exposure

through live web events

showcasing clinical

capabilities

Enhance clinical

capabilities with a

robotic suite

15,000 Interventional

Standard Labs

ODYSSEY

Business Model

Capital Revenue

Recurring Revenue

Niobe

Odyssey

Workstation

Odyssey

Cinema

•

141 Niobe

systems installed

•

2,500 EP labs worldwide

•

20+% growth; ~60% margin

•

25% growth (YTD 2010 vs. 2009)

•

80% margin

Capital Driven

•

Technical service

•

Software license

Niobe

Utilization

•

Stereotaxis

disposables

•

Royalty from J&J BWI

27% growth (2009 vs. 2008); 65+% margin

13

14

Strategies to Accelerate Growth

$0.0

$4.0

$8.0

$12.0

$16.0

Q1

Q2

Q3

Q4

2008

2009

2010

$11.2

$8.8

$7.2

$7.3

$5.0

$10.2

$12.4

$6.3

$11.2

$7.7

New Orders to Backlog

Revenue Momentum

Recurring Revenue

$ millions

$ millions

$0

$2

$4

$6

$8

$10

$12

$14

$16

Q1

Q2

Q3

Q4

2008

2009

2010

$7.0

$11.1

$10.6

$10.7

$12.6

$15.0

$10.6

$13.3

$12.1

$14.1

$ millions

Stereotaxis

Financial Update

15

$0.0

$4.0

$8.0

$12.0

Q1

Q2

Q3

Q4

2008

2009

2010

Total Inventory

-$20.0

-$15.0

-$10.0

-$5.0

$0.0

$5.0

Q1

Q2

Q3

Q4

2008

2009

2010

Cash Flow (Burn)

$0.0

$5.0

$10.0

$15.0

$20.0

$25.0

Q1

Q2

Q3

Q4

2008

2009

2010

Operating Expenses

55.0%

60.0%

65.0%

70.0%

75.0%

Q1

Q2

Q3

Q4

2008

2009

2010

Gross Margin Percentage

$ millions

$ millions

$ millions

65.5%

68.9%

72.5%

60.8%

63.1%

65.5%

67.8%

67.6%

67.3%

$17.8

$14.8

$14.0

$18.7

$14.6

$16.1

$13.3

$14.6

$15.3

-$12.6

-$11.4

-$6.4

-$7.6

-$5.8

-$5.6

-$3.5

-$4.5

-$2.9

$10.5

$8.1

$4.9

$9.6

$7.5

$8.4

$7.0

$8.1

$4.4

67.2%

$15.8

$4.3

-$7.9

Stereotaxis

Financial Update

16

Liquidity

$3.0

$1.3

$3.6

$0

$2

$4

$6

$8

$10

2010

Operating Cash Flow Ex A/R

BWI Debt

Accounts Receivable

Q2 2010 Cash Burn Analysis

$ Millions

$7.9

$ Millions

17

* Cash burn includes repayment of Biosense Webster advance. 

Investment Considerations

Two innovative technology platforms:

Niobe

®

Magnetic Navigation System

Odyssey

™

Enterprise Solutions

Substantial IP portfolio

Large, fast growing (+20%) cardiology ablation market

Poised for continued growth in electrophysiology (EP)

Expansion into new markets

New geographic opportunities

Broad clinical applications beyond EP

Multi-dimensional strategy to accelerate growth

18

Q & A

19